MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuances
of common stock and...
$234,762K
Proceeds from issuance of
common stock under...
$2,229K
Proceeds from exercise of
stock options and...
$1,651K
Maturities of marketable
securities
$617,543K
Net cash provided by
financing activities
$238,642K
Net cash provided by
(used in) investing...
$147,853K
Canceled cashflow
$469,690K
Net increase
(decrease) in cash, cash...
$137,030K
Canceled cashflow
$249,465K
Stock-based compensation
$37,965K
Accrued expenses and
other current...
$17,310K
Amortization of operating
lease right-of-use...
$10,116K
Depreciation and
amortization
$8,740K
Loss on disposal of
property and equipment
-$89K
Purchases of marketable
securities
$455,688K
Purchases of property and
equipment
$14,002K
Net cash used in
operating activities
-$249,465K
Canceled cashflow
$74,220K
Net loss
-$264,457K
Deferred revenue
-$36,980K
Net accretion of
discount on marketable...
$10,322K
Prepaid expenses and
other assets
$6,229K
Operating lease
liabilities
-$5,067K
Accounts payable
-$630K
Back
Back
Cash Flow
source: myfinsight.com
Nurix Therapeutics, Inc. (NRIX)
Nurix Therapeutics, Inc. (NRIX)